Jan Konvalinka

List of Publications by Year in descending order

143 papers	4,766 citations	87888 38 h-index	123424 61 g-index
147 all docs	147 docs citations	147 times ranked	4705 citing authors

#	Article	IF	Citations
1	Predicting Effects of Site-Directed Mutagenesis on Enzyme Kinetics by QM/MM and QM Calculations: A Case of Glutamate Carboxypeptidase II. Journal of Physical Chemistry B, 2022, 126, 132-143.	2.6	9
2	structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor. Antiviral Research, 2021, 185, 104971.	4.1	5
3	Enyzmes | HIV Protease. , 2021, , 264-269.		0
4	Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase. Molecules, 2021, 26, 1007.	3.8	8
5	Re-emerging Aspartic Protease Targets: Examining Cryptococcus neoformans Major Aspartyl Peptidase 1 as a Target for Antifungal Drug Discovery. Journal of Medicinal Chemistry, 2021, 64, 6706-6719.	6.4	14
6	Synthesis and In Vitro Evaluation of C-7 and C-8 Luteolin Derivatives as Influenza Endonuclease Inhibitors. International Journal of Molecular Sciences, 2021, 22, 7735.	4.1	7
7	Structure-activity relationship and biochemical evaluation of novel fibroblast activation protein and prolyl endopeptidase inhibitors with Î±-ketoamide warheads. European Journal of Medicinal Chemistry, 2021, 224, 113717.	5.5	6
8	The role of the biotin linker in polymer antibody mimetics, iBodies, in biochemical assays. Polymer Chemistry, 2021, 12, 6009-6021.	3.9	3
9	The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody). Journal of Biological Chemistry, 2021, 297, 101342.	3.4	2
10	Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors. European Journal of Medicinal Chemistry, 2020, 208, 112754.	5.5	21
11	Identification of Novel Carbonic Anhydrase IX Inhibitors Using High-Throughput Screening of Pooled Compound Libraries by DNA-Linked Inhibitor Antibody Assay (DINA). SLAS Discovery, 2020, 25, 1026-1037.	2.7	2
12	Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2020, 1868, 140409.	2.3	39
13	The yeast proteases Ddi1 and Wss1 are both involved in the DNA replication stress response. DNA Repair, 2019, 80, 45-51.	2.8	31
14	MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. PLoS Biology, 2019, 17, e3000354.	5.6	94
15	Exploiting the unique features of Zika and Dengue proteases for inhibitor design. Biochimie, 2019, 166, 132-141.	2.6	25
16	Investigation of flexibility of neuraminidase 150-loop using tamiflu derivatives in influenza A viruses H1N1 and H5N1. Bioorganic and Medicinal Chemistry, 2019, 27, 2935-2947.	3.0	15
17	Inhibitorâ€“Polymer Conjugates as a Versatile Tool for Detection and Visualization of Cancer-Associated Carbonic Anhydrase Isoforms. ACS Omega, 2019, 4, 6746-6756.	3.5	10
18	Capturing a dynamically interacting inhibitor by paramagnetic NMR spectroscopy. Physical Chemistry Chemical Physics, 2019, 21, 5661-5673.	2.8	21

#	Article	IF	Citations
19	Tris-(Nitrilotriacetic Acid)-Decorated Polymer Conjugates as Tools for Immobilization and Visualization of His-Tagged Proteins. Catalysts, 2019, 9, 1011.	3.5	6
20	A novel PSMA/GCPIIâ€deficient mouse model shows enlarged seminal vesicles upon aging. Prostate, 2019, 79, 126-139.	2.3	3
21	GCPII and its close homolog GCPIII from a neuropeptidase to a cancer marker and beyond. Frontiers in Bioscience - Landmark, 2019, 24, 648-687.	3.0	8
22	Inhibitorâ€“GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles. Molecular Pharmaceutics, 2018, 15, 2932-2945.	4.6	25
23	Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy. Analytica Chimica Acta, 2018, 997, 44-51.	5.4	18
24	DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors. Biochemical Journal, 2018, 475, 3847-3860.	3.7	5
25	Identification of Protein Targets of Bioactive Small Molecules Using Randomly Photomodified Probes. ACS Chemical Biology, 2018, 13, 3333-3342.	3.4	9
26	The calciumâ€binding site of human glutamate carboxypeptidase II is critical for dimerization, thermal stability, and enzymatic activity. Protein Science, 2018, 27, 1575-1584.	7.6	5
27	Kinetic, Thermodynamic, and Structural Analysis of Drug Resistance Mutations in Neuraminidase from the 2009 Pandemic Influenza Virus. Viruses, 2018, 10, 339.	3.3	17
28	Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation. Scientific Reports, 2018, 8, 10438.	3.3	12
29	DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening. Nucleic Acids Research, 2017, 45, e10-e10.	14.5	11
30	Inhibitor-Decorated Polymer Conjugates Targeting Fibroblast Activation Protein. Journal of Medicinal Chemistry, 2017, 60, 8385-8393.	6.4	21
31	Mouse glutamate carboxypeptidaseÂ<scp>II</scp> (<scp>GCPII</scp>) has a similar enzyme activity and inhibition profile but a different tissue distribution to human <scp>GCPII</scp>. FEBS Open Bio, 2017, 7, 1362-1378.	2.3	15
32	Random protein sequences can form defined secondary structures and are well-tolerated in vivo. Scientific Reports, 2017, 7, 15449.	3.3	68
33	Comparison of human glutamate carboxypeptidases <scp>II</scp> and <scp>III</scp> reveals their divergent substrate specificities. FEBS Journal, 2016, 283, 2528-2545.	4.7	21
34	Human DNA-Damage-Inducible 2 Protein Is Structurally and Functionally Distinct from Its Yeast Ortholog. Scientific Reports, 2016, 6, 30443.	3.3	46
35	iBodies: Modular Synthetic Antibody Mimetics Based on Hydrophilic Polymers Decorated with Functional Moieties. Angewandte Chemie, 2016, 128, 2402-2406.	2.0	0
36	Kinetic, thermodynamic and structural analysis of tamiphosphor binding to neuraminidase of H1N1 (2009) pandemic influenza. European Journal of Medicinal Chemistry, 2016, 121, 100-109.	5.5	9

#	Article	IF	Citations
37	A Modular Synthesis of Nâ€Benzotriazole Ureas Using Alkylation of 5â€Nitrobenzotriazole. ChemistrySelect, 2016, 1, 101-107.	1.5	6
38	Stimulated Emission Depletion Nanoscopy Reveals Time-Course of Human Immunodeficiency Virus Proteolytic Maturation. ACS Nano, 2016, 10, 8215-8222.	14.6	30
39	Structural studies of the yeast DNA damage-inducible protein Ddi1 reveal domain architecture of this eukaryotic protein family. Scientific Reports, 2016, 6, 33671.	3.3	44
40	Synthesis and evaluation of 2-pyridinylpyrimidines as inhibitors of HIV-1 structural protein assembly. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3487-3490.	2.2	4
41	iBodies: Modular Synthetic Antibody Mimetics Based on Hydrophilic Polymers Decorated with Functional Moieties. Angewandte Chemie - International Edition, 2016, 55, 2356-2360.	13.8	31
42	Specific Inhibitors of HIV Capsid Assembly Binding to the C-Terminal Domain of the Capsid Protein: Evaluation of 2-Arylquinazolines as Potential Antiviral Compounds. Journal of Medicinal Chemistry, 2016, 59, 545-558.	6.4	39
43	Inhibitor and Substrate Binding Induced Stability of HIV-1 Protease against Sequential Dissociation and Unfolding Revealed by High Pressure Spectroscopy and Kinetics. PLoS ONE, 2015, 10, e0119099.	2.5	6
44	Structural and Biochemical Characterization of a Novel Aminopeptidase from Human Intestine. Journal of Biological Chemistry, 2015, 290, 11321-11336.	3.4	14
45	Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor. Nature Communications, 2015, 6, 6461.	12.8	25
46	Design of Highly Potent Urea-Based, Exosite-Binding Inhibitors Selective for Glutamate Carboxypeptidase II. Journal of Medicinal Chemistry, 2015, 58, 4357-4363.	6.4	29
47	Retroviral proteases and their roles in virion maturation. Virology, 2015, 479-480, 403-417.	2.4	109
48	Malonate-based inhibitors of mammalian serine racemase: Kinetic characterization and structure-based computational study. European Journal of Medicinal Chemistry, 2015, 89, 189-197.	5.5	49
49	GS-8374, a Prototype Phosphonate-Containing Inhibitor of HIV-1 Protease, Effectively Inhibits Protease Mutants with Amino Acid Insertions. Journal of Virology, 2014, 88, 3586-3590.	3.4	9
50	Thermodynamic and structural analysis of <scp>HIV</scp> protease resistance to darunavirÂâ€“Âanalysis of heavily mutated patientâ€derived <scp>HIV</scp>â€1 proteases. FEBS Journal, 2014, 281, 1834-1847.	4.7	48
51	Detection and quantitation of glutamate carboxypeptidase II in human blood. Prostate, 2014, 74, 768-780.	2.3	14
52	Induced Maturation of Human Immunodeficiency Virus. Journal of Virology, 2014, 88, 13722-13731.	3.4	29
53	Structural and biochemical characterization of the folylâ€polyâ€Î³â€<scp>l</scp>â€glutamate hydrolyzing activity of human glutamate carboxypeptidase <scp>II</scp>. FEBS Journal, 2014, 281, 3228-3242.	4.7	22
54	Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery. Bioorganic and Medicinal Chemistry, 2014, 22, 4099-4108.	3.0	37

#	Article	IF	Citations
55	Unorthodox Inhibitors of HIV Protease: Looking Beyond Active-site-directed Peptidomimetics. Current Pharmaceutical Design, 2014, 20, 3389-3397.	1.9	3
56	Ion specific effects of alkali cations on the catalytic activity of HIV-1 protease. Faraday Discussions, 2013, 160, 359-370.	3.2	10
57	Simian Immunodeficiency Virus Retropepsin. , 2013, , 204-207.		0
58	Miscellaneous Viral Retropepsins. , 2013, , 237-240.		0
59	Spumapepsins. , 2013, , 245-248.		0
60	Glutamate carboxypeptidase II does not process amyloidâ€β2 peptide. FASEB Journal, 2013, 27, 2626-2632.	0.5	4
61	Derivatization chemistry of the double-decker dicobalt sandwich ion targeted to design biologically active substances. Pure and Applied Chemistry, 2012, 84, 2243-2262.	1.9	8
62	Mutations in HIV-1gagandpolCompensate for the Loss of Viral Fitness Caused by a Highly Mutated Protease. Antimicrobial Agents and Chemotherapy, 2012, 56, 4320-4330.	3.2	40
63	Structure-Aided Design of Novel Inhibitors of HIV Protease Based on a Benzodiazepine Scaffold. Journal of Medicinal Chemistry, 2012, 55, 10130-10135.	6.4	53
64	Novel Substrate-Based Inhibitors of Human Glutamate Carboxypeptidase II with Enhanced Lipophilicity. Journal of Medicinal Chemistry, 2011, 54, 7535-7546.	6.4	20
65	Urea and Guanidinium Induced Denaturation of a Trp-Cage Miniprotein. Journal of Physical Chemistry B, 2011, 115, 8910-8924.	2.6	56
66	Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry. Current Drug Targets, 2011, 12, 1037-1055.	2.1	46
67	Medicinal Application ofÂCarboranes. , 2011, , 41-70.		12
68	HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat. Retrovirology, 2011, 8, 70.	2.0	23
69	Chapter 3. Glutamate Carboxypeptidase II as a Therapeutic Target. RSC Drug Discovery Series, 2011, , 62-95.	0.3	2
70	A Reliable Docking/Scoring Scheme Based on the Semiempirical Quantum Mechanical PM6-DH2 Method Accurately Covering Dispersion and H-Bonding: HIV-1 Protease with 22 Ligands. Journal of Physical Chemistry B, 2010, 114, 12666-12678.	2.6	116
71	Random mutagenesis of human serine racemase reveals residues important for the enzymatic activity. Collection of Czechoslovak Chemical Communications, 2010, 75, 59-79.	1.0	3
72	Molecular Characterization of Clinical Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir. Journal of Virology, 2009, 83, 8810-8818.	3.4	43

#	Article	IF	Citations
73	Prostateâ€specific membrane antigen and its truncated form PSMâ€². Prostate, 2009, 69, 471-479.	2.3	19
74	Czech bibliometric system fosters mediocre research. Nature, 2009, 460, 1079-1079.	27.8	2
75	Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III. FEBS Journal, 2009, 276, 4448-4462.	4.7	33
76	Reaction Mechanism of Glutamate Carboxypeptidase II Revealed by Mutagenesis, X-ray Crystallography, and Computational Methods. Biochemistry, 2009, 48, 4126-4138.	2.5	56
77	Ion specific effects of sodium and potassium on the catalytic activity of HIV-1 protease. Physical Chemistry Chemical Physics, 2009, 11, 7599.	2.8	36
78	Recombinant human serine racemase: Enzymologic characterization and comparison with its mouse ortholog. Protein Expression and Purification, 2009, 63, 62-67.	1.3	38
79	Current and Novel Inhibitors of HIV Protease. Viruses, 2009, 1, 1209-1239.	3.3	102
80	Kinetics of the dimerization of retroviral proteases: The â€œfireman's gripâ€•and dimerization. Protein Science, 2009, 12, 2173-2182.	7.6	27
81	Hydroxamic Acids As a Novel Family of Serine Racemase Inhibitors: Mechanistic Analysis Reveals Different Modes of Interaction with the Pyridoxal-5â€²-phosphate Cofactor. Journal of Medicinal Chemistry, 2009, 52, 6032-6041.	6.4	33
82	Design of HIV Protease Inhibitors Based on Inorganic Polyhedral Metallacarboranes. Journal of Medicinal Chemistry, 2009, 52, 7132-7141.	6.4	132
83	Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate, 2008, 68, 171-182.	2.3	42
84	Anomalous adsorptive properties of HIV protease: Indication of two-dimensional crystallization?. Colloids and Surfaces B: Biointerfaces, 2008, 64, 145-149.	5.0	3
85	Expression and distribution of â€˜high affinityâ€™ glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system. Journal of Anatomy, 2008, 213, 539-546.	1.5	50
86	Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Research, 2008, 78, 275-277.	4.1	7
87	Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir. Protein Science, 2008, 17, 1555-1564.	7.6	24
88	Inorganic Polyhedral Metallacarborane Inhibitors of HIV Protease: A New Approach to Overcoming Antiviral Resistance. Journal of Medicinal Chemistry, 2008, 51, 4839-4843.	6.4	90
89	Structural Basis of Interactions between Human Glutamate Carboxypeptidase II and Its Substrate Analogs. Journal of Molecular Biology, 2008, 376, 1438-1450.	4.2	79
90	Ninety-Nine Is Not Enough: Molecular Characterization of Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Protease Mutants with Insertions in the Flap Region. Journal of Virology, 2008, 82, 5869-5878.	3.4	39

#	Article	IF	Citations
91	A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism. PLoS Medicine, 2007, 4, e36.	8.4	146
92	Expression of glutamate carboxypeptidase II in human brain. Neuroscience, 2007, 144, 1361-1372.	2.3	116
93	Molecular Analysis of the HIV-1 Resistance Development: Enzymatic Activities, Crystal Structures, and Thermodynamics of Nelfinavir-resistant HIV Protease Mutants. Journal of Molecular Biology, 2007, 374, 1005-1016.	4.2	74
94	Structural Insight into the Pharmacophore Pocket of Human Glutamate Carboxypeptidase II. Journal of Medicinal Chemistry, 2007, 50, 3267-3273.	6.4	71
95	A high-resolution structure of ligand-free human glutamate carboxypeptidase II. Acta Crystallographica Section F: Structural Biology Communications, 2007, 63, 150-153.	0.7	48
96	Mapping of the active site of glutamate carboxypeptidaseâ€ƒII by siteâ€directed mutagenesis. FEBS Journal, 2007, 274, 4731-4741.	4.7	25
97	HIV-1 Protease Mutations and Inhibitor Modifications Monitored on a Series of Complexes. Structural Basis for the Effect of the A71V Mutation on the Active Site. Journal of Medicinal Chemistry, 2006, 49, 5777-5784.	6.4	17
98	Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants. Journal of Clinical Virology, 2006, 36, 50-59.	3.1	12
99	On the role of theRconfiguration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0â€…Ã… resolution. Acta Crystallographica Section D: Biological Crystallography, 2006, 62, 489-497.	2.5	1
100	Biochemical characterization of human glutamate carboxypeptidase III. Journal of Neurochemistry, 2006, 101, 682-696.	3.9	51
101	Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO Journal, 2006, 25, 1375-1384.	7.8	241
102	Capillary electrophoresis method for determination ofD-serine and its application for monitoring of serine racemase activity. Electrophoresis, 2006, 27, 2558-2566.	2.4	36
103	Dual Substrate and Reaction Specificity in Mouse Serine Racemase:â€‰ Identification of High-Affinity Dicarboxylate Substrate and Inhibitors and Analysis of the Î²-Eliminase Activity. Biochemistry, 2005, 44, 13091-13100.	2.5	106
104	Homology modeling and SAR analysis of Schistosoma japonicum cathepsin D (SjCD) with statin inhibitors identify a unique active site steric barrier with potential for the design of specific inhibitors. Biological Chemistry, 2005, 386, 339-349.	2.5	16
105	From nonpeptide toward noncarbon protease inhibitors: Metallacarboranes as specific and potent inhibitors of HIV protease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15394-15399.	7.1	279
106	Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir. Journal of Clinical Virology, 2005, 33, 319-323.	3.1	6
107	Characterisation of Mutated Proteinases Derived from HIV-Positive Patients: Enzyme Activity, Vitality and Inhibition. Collection of Czechoslovak Chemical Communications, 2004, 69, 703-714.	1.0	6
108	Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. FEBS Journal, 2004, 271, 2782-2790.	0.2	29

#	Article	IF	Citations
109	Role of hydroxyl group and R/S configuration of isostere in binding properties of HIV-1 protease inhibitors. FEBS Journal, 2004, 271, 4451-4461.	0.2	8
110	Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex. Acta Crystallographica Section D: Biological Crystallography, 2004, 60, 1943-1948.	2.5	18
111	A Phenylnorstatine Inhibitor Binding to HIV-1 Protease:Â Geometry, Protonation, and Subsiteâ˜Pocket Interactions Analyzed at Atomic Resolution. Journal of Medicinal Chemistry, 2004, 47, 2030-2036.	6.4	22
112	Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Science, 2004, 13, 1627-1635.	7.6	93
113	Proteinases of betaretroviruses bind single-stranded nucleic acids through a novel interaction module, the G-patch. FEBS Letters, 2004, 576, 271-276.	2.8	28
114	Determining and Overcoming Resistance to HIV Protease Inhibitors. Current Drug Targets Infectious Disorders, 2004, 4, 137-152.	2.1	23
115	Spumapepsins. , 2004, , 188-190.		0
116	Miscellaneous viral retropepsins. , 2004, , 185-187.		0
117	Simian immunodeficiency virus retropepsin. , 2004, , 158-160.		0
118	An Ethylenamine Inhibitor Binds Tightly to Both Wild Type and Mutant HIV-1 Proteases. Structure and Energy Study. Journal of Medicinal Chemistry, 2003, 46, 1636-1644.	6.4	11
119	Mouse brain serine racemase catalyzes specific elimination ofL-serine to pyruvate. FEBS Letters, 2003, 535, 44-48.	2.8	78
120	Hydroxyethylamine Isostere of an HIV-1 Protease Inhibitor Prefers Its Amine to the Hydroxy Group in Binding to Catalytic Aspartates. A Synchrotron Study of HIV-1 Protease in Complex with a Peptidomimetic Inhibitor. Journal of Medicinal Chemistry, 2002, 45, 1432-1438.	6.4	18
121	The Murine Endogenous Retrovirus MIA14 Encodes an Active Aspartic Proteinase That Is Functionally Similar to Proteinases from D-Type Retroviruses. Archives of Biochemistry and Biophysics, 2002, 398, 261-268.	3.0	11
122	Unusual Binding Mode of an HIV-1 Protease Inhibitor Explains its Potency against Multi-drug-resistant Virus Strains. Journal of Molecular Biology, 2002, 324, 739-754.	4.2	46
123	Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. Journal of Neurochemistry, 2002, 80, 477-487.	3.9	113
124	Analysis of substrate specificity of HIV protease species. , 2002, , 474-475.		1
125	A distinct binding mode of a hydroxyethylamine isostere inhibitor of HIV-1 protease. Acta Crystallographica Section D: Biological Crystallography, 2001, 57, 472-476.	2.5	8
126	Cell-Based Fluorescence Assay for Human Immunodeficiency Virus Type 1 Protease Activity. Antimicrobial Agents and Chemotherapy, 2001, 45, 2616-2622.	3.2	41

#	Article	IF	Citations
127	Systematic mutational analysis of the activeâ€site threonine of HIVâ€1 proteinase: Rethinking the â€œfireman's gripâ€•hypothesis. Protein Science, 2000, 9, 1631-1641.	7.6	39
128	A Picomolar Inhibitor of Resistant Strains of Human Immunodeficiency Virus Protease Identified by a Combinatorial Approach. Archives of Biochemistry and Biophysics, 2000, 382, 22-30.	3.0	18
129	Synthesis of library of HIV proteases inhibitors. , 1999, , .		1
130	Potency Comparison of Peptidomimetic Inhibitors against HIV-1 and HIV-2 Proteinases: Design of Equipotent Lead Compounds. Archives of Biochemistry and Biophysics, 1997, 341, 62-69.	3.0	18
131	Configurations of Diastereomeric Hydroxyethylene Isosteres Strongly Affect Biological Activities of a Series of Specific Inhibitors of Human-Immunodeficiency-Virus Proteinase. FEBS Journal, 1997, 250, 559-566.	0.2	25
132	A Modular Approach to HIV-1 Proteinase Inhibitor Design. Biochemical and Biophysical Research Communications, 1996, 222, 38-43.	2.1	16
133	Proteolytic Processing of Particle-Associated Retroviral Polyproteins by Homologous and Heterologous Viral Proteinases. FEBS Journal, 1995, 228, 191-198.	0.2	1
134	Proteolytic Processing of Particle-Associated Retroviral Polyproteins by Homologous and Heterologous Viral Proteinases. FEBS Journal, 1995, 228, 191-198.	0.2	42
135	A possible regulation of negative factor (Nef) activity of human immunodeficiency virus type 1 by the viral protease. FEBS Journal, 1994, 223, 589-593.	0.2	58
136	Short, tight-binding inhibitors of HIV-1 protease with dipeptide isosteres at the P1-P1â€² site. , 1993, , 803-804.		0
137	Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic-hydrophobic- or -aromatic-Pro- cleavage sites. Biochemistry, 1992, 31, 5193-5200.	2.5	107
138	Reduced-bond tight-binding inhibitors of HIV-1 protease Fine tuning of the enzyme subsite specificity. FEBS Letters, 1992, 298, 9-13.	2.8	35
139	Specificity studies on retroviral proteinase from myeloblastosis-associated virus. Biochemistry, 1991, 30, 3437-3443.	2.5	32
140	High-level expression of enzymatically active bovine leukemia virus proteinase inE. coli. FEBS Letters, 1991, 287, 129-132.	2.8	21
141	Subsite specificity of the proteinase from myeloblastosis associated virus. FEBS Letters, 1991, 282, 73-76.	2.8	13
142	Sub-site preferences of the aspartic proteinase from the human immunodeficiency virus, HIV-1. FEBS Letters, 1990, 268, 35-38.	2.8	50
143	Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases. Biochemical and Biophysical Research Communications, 1990, 171, 439-444.	2.1	76